SOURCE: The Cognition Group

The Cognition Group

December 17, 2009 13:46 ET

TCG Leads the Way in Global CNS Clinical Trials

Advances in Technology Help Better Determine Which Drugs Are Successful in CNS Trials

NEWARK, DE--(Marketwire - December 17, 2009) - The Cognition Group (TCG) has updated its hardware for the Signal Enhancement System (SES). This technological enhancement will allow patient interviews to be recorded and viewed in a more precise, higher quality format and will further improve international clinical trials.

Clinical trials in the Central Nervous System (CNS) have been riddled with human error as long as they have existed. Problems include inconsistent or biased ratings, patients with incorrect diagnoses participating in the study, or even rating of the wrong interview. All of these issues have decreased the signal in CNS clinical trials.

SES is a cost effective and easily implemented system that resolves these issues through interview quality control, study assessment standardization, and scale rating integrity at the investigating sites. The innovative system, which has been used in CNS clinical trials for the last three years, not only ensures that interviews are consistently conducted according to protocol, but also facilitates expert and consensus ratings.

Data presented at recent conferences show that the SES controls for raters' enrolment bias and expectancy bias while ensuring that patients with the correct diagnosis are entered into the study. It addresses in-study rater variance by identifying raters' nonconformity to pre-set rating standards, consequently enhancing data quality. The technology's strength is based on more focused patient evaluation and controlled impact of inconsistent rater performance on trial outcomes.

Recently, TCG has updated all of its hardware that it distributes to sites by replacing all of its laptops with a newer, faster model; adding a 180 degree, higher pixel motion-detecting camera; and including a high quality USB microphone that can clearly record conversation up to 50 feet away. "We are very excited about this update," said Subhash Goswami, Chief Operating Officer of TCG. "SES has revolutionized the way in which CNS clinical trials are conducted. Updating the hardware allows us to further improve the industry standards and greatly reduce errors in clinical trials."

For additional information on SES and other TCG products, go to To interview Chief Operating Officer Subhash Goswami, please contact Jonathan Abramson at Video and clinical evidence from studies conducted over the past three years can be provided by request.

About TCG:

(TCG) is a global company that provides scientific knowledge about the central nervous system, technological innovation and project management expertise to the biopharmaceutical industry. TCG is dedicated to providing solutions that promote clinical research excellence and enhance the administration and collection of data for clinical trials. Primary services include the customized rater training program, centralized ratings and computerized cognitive assessment. TCG also provides a variety of complimentary services which includes consultancy on cognitive battery design, statistical analysis and report writing.

Contact Information

  • Contact Information:
    Jonathan Abramson
    Director of Communications
    949.369.1300 (Office)
    Email Contact